6 May 2025NewsAmericasMarisa Woutersen

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

More on this story

Big Pharma
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

More on this story

Big Pharma
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Americas
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.